Abstract

Locoregional, as well as metastatic renal cell carcinoma, tends to relapse after nephrectomy or metastasectomy. Adjuvant therapy seems to be an effective strategy to reduce the risk of recurrence. All anti-VEGF tyrosine kinase inhibitors except sunitinib have failed to show any benefit in the adjuvant setting in patients with locally advanced disease and an intermediate-to-high chance of recurrence. On the other hand, immune checkpoint inhibitors, which are now used in the first-line in the metastatic setting, are being tested in the adjuvant setting. Pembrolizumab has shown benefit in the adjuvant setting in patients with a high risk of recurrence or with resected metastatic disease with no evidence of disease. Results for other checkpoint inhibitors are still awaited.

Plain language summary

Advanced and metastatic kidney cancer often tend to relapse after surgery. Treatment maintenance after surgery could be an effective strategy to reduce the risk of recurrence. Anti-VEGF tyrosine kinase inhibitors are the standard of care in the treatment of metastatic kidney cancer. However, they have all (but one) failed to prevent the occurrence of metastases in advanced nonmetastatic kidney cancer. On the other hand, immunotherapy is now being tested as a postsurgery treatment to prevent disease recurrence. Pembrolizumab has shown efficacy in preventing recurrence and is now approved as a postsurgery drug in advanced kidney cancer.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
MedlineGoogle Scholar
2. Cheaib JG, Patel HD, Johnson MH et al. Stage-specific conditional survival in renal cell carcinoma after nephrectomy. Urol. Oncol. 38(1), 6.e1–6.e7 (2020).
MedlineGoogle Scholar
3. Lee Z, Jegede OA, Haas NB et al. Local recurrence following resection of intermediate-high risk non-metastatic renal cell carcinoma: an anatomic classification and analysis of the ASSURE (ECOG-ACRIN E2805) adjuvant trial. J. Urol. 203(4), 684–689 (2020).
MedlineGoogle Scholar
4. Eisen T, Frangou E, Oza B et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. JCO 38(34), 4064–4075 (2020).
Medline CASGoogle Scholar
5. Blick C, Ritchie AWS, Eisen T, Stewart GD. Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials. Nat. Rev. Urol. 14(12), 753–759 (2017).
MedlineGoogle Scholar
6. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. JCO 19(6), 1649–1657 (2001).
Medline CASGoogle Scholar
7. Patard J-J, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. JCO 22(16), 3316–3322 (2004).
MedlineGoogle Scholar
8. Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 97(7), 1663–1671 (2003).
MedlineGoogle Scholar
9. Larroquette M, Peyraud F, Domblides C et al. Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives. Cancer Treat. Rev. 97, 102207 (2021).
Medline CASGoogle Scholar
10. Blackmur JP, Gaba F, Fernando D et al. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma. Urol. Oncol. 39(7), 438.e11–438.e21 (2021).
MedlineGoogle Scholar
11. Haas NB, Manola J, Uzzo RG et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032), 2008–2016 (2016).
Medline CASGoogle Scholar
12. Ravaud A, Motzer RJ, Pandha HS et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375(23), 2246–2254 (2016).
Medline CASGoogle Scholar
13. FDA. Research C for DE and FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sunitinib-malate-adjuvant-treatment-renal-cell-carcinoma
Google Scholar
14. Gross-Goupil M, Kwon TG, Eto M et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann. Oncol. 29(12), 2371–2378 (2018).
Medline CASGoogle Scholar
15. Motzer RJ, Haas NB, Donskov F et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J. Clin. Oncol. 35(35), 3916–3923 (2017).
Medline CASGoogle Scholar
16. Choueiri TK, Tomczak P, Park SH et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: results from 30-month follow-up of KEYNOTE-564. JCO 40(Suppl. 6), 290 (2022).
Google Scholar
17. Choueiri TK, Tomczak P, Park SH et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385(8), 683–694 (2021).
Medline CASGoogle Scholar
18. FDA. Research C for DE and FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma (2021). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma
Google Scholar
19. Oza B, Frangou E, Smith B et al. RAMPART: a phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp. Clin. Trials 108, 106482 (2021).
MedlineGoogle Scholar
20. Uzzo R, Bex A, Rini BI et al. A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010). JCO 35(Suppl. 15), TPS4598 (2017).
Google Scholar
21. Bex A, Russo P, Tomita Y et al. A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high risk of relapse after radical or partial nephrectomy (CheckMate 914). JCO 38(Suppl. 15), TPS5099 (2020).
Google Scholar
22. Harshman LC, Puligandla M, Haas NB et al. PROSPER: a phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). JCO 37(Suppl. 7), TPS684 (2019). •• Shows mechanism of resistance to anti-VEGF tyrosine kinase inhibitors.
Google Scholar
23. Porta C, Chiellino S. ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann. Transl. Med. 4(Suppl. 1), S14 (2016).
MedlineGoogle Scholar
24. Santoni M, Buti S, Conti A et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 10(4), 517–522 (2015).
MedlineGoogle Scholar
25. Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev. Urol. 8(1), 1–7 (2006).
MedlineGoogle Scholar
26. Fallara G, Bandini M, Larcher A et al. High-risk surgically resected renal cell carcinoma: is there a role for adjuvant VEGF-TKI inhibitors? Curr. Probl. Cancer 45(6), 100759 (2021).
MedlineGoogle Scholar
27. Laukhtina E, Quhal F, Mori K et al. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urol. Oncol. 39(11), 764–773 (2021).
Medline CASGoogle Scholar
28. Brown LC, Zhang T, George DJ. The role of targeted therapy in the management of high-risk resected kidney cancer: what have we learned and how will it inform future adjuvant trials. Cancer J. 26(5), 376–381 (2020).
Medline CASGoogle Scholar
29. Wood E, Donin N, Shuch B. Adjuvant therapy for localized high-risk renal cell carcinoma. Urol. Clin. North Am. 47(3), 345–358 (2020).
MedlineGoogle Scholar
30. Laukhtina E, Quhal F, Mori K et al. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. Eur. Urol. Oncol. 5(1), 120–124 (2022).
MedlineGoogle Scholar
31. Marconi L, Sun M, Beisland C et al. Prevalence, disease-free, and overall survival of contemporary patients with renal cell carcinoma eligible for adjuvant checkpoint inhibitor trials. Clin. Genitourin. Cancer 19(2), e92–e99 (2021).
MedlineGoogle Scholar
32. Bedke J, Albiges L, Capitanio U et al. 2021 Updated European Association of Urology Guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur. Urol. 81(2), 134–137 (2022).
Medline CASGoogle Scholar
33. Pandey A. KEYNOTE-564: adjuvant immunotherapy for renal cell carcinoma. Indian J. Urol. 38(1), 75–76 (2022). • Arguments against pembrolizumab use in the adjuvant setting.
MedlineGoogle Scholar
34. Flammia RS, Hoeh B, Hohenhorst L et al. Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab. Semin. Oncol. 49(2), 136–140 (2022).
Medline CASGoogle Scholar
35. Eggermont AM, Meshcheryakov A, Atkinson V et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Eur. J. Cancer 158, 156–168 (2021). • Shows potential predictive biomarkers that might help predict response to adjuvant anti-VEGF tyrosine kinase inhibitors.
Medline CASGoogle Scholar
36. George DJ, Martini J-F, Staehler M et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory pharmacogenomic analysis. Clin. Cancer Res. 25(4), 1165–1173 (2019).
Medline CASGoogle Scholar
37. Rini B, Goddard A, Knezevic D et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 16(6), 676–685 (2015).
Medline CASGoogle Scholar
38. Rini BI, Escudier B, Martini J-F et al. Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant sunitinib. Clin. Cancer Res. 24(18), 4407–4415 (2018).
Medline CASGoogle Scholar
39. George DJ, Martini J-F, Staehler M et al. Immune biomarkers predictive for disease-free survival with adjuvant sunitinib in high-risk locoregional renal cell carcinoma: from randomized phase III S-TRAC study. Clin. Cancer Res. 24(7), 1554–1561 (2018).
Medline CASGoogle Scholar

Vol. 15, No. 2

Metrics

Downloaded 176 times

History

Received 26 May 2022

Accepted 19 December 2022

Published online 5 January 2023

Published in print February 2023

Information

Keywords

Author contributions

HR Kourie and J Zouein contributed to the conception of the study; J Zouein and N Naim contributed to the review of the literature; J Zouein and N Naim drafted the manuscript; HR Kourie contributed to review of the manuscript.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?

Abstract

Plain language summary

References